Document is current
Any future updates will be listed below
-
Authors
Rodríguez-Lobato, Luis Gerardo https://orcid.org/0000-0001-5694-0921
de Daniel, Anna https://orcid.org/0009-0007-7568-2527
Pereira, Arturo https://orcid.org/0000-0003-2711-422X
Fernández de Larrea, Carlos https://orcid.org/0000-0003-4930-9255
Tovar, Natalia https://orcid.org/0000-0001-5525-476X
Cibeira, M. Teresa https://orcid.org/0000-0002-4036-754X
Moreno, David F.
Mateos, Jose Miguel https://orcid.org/0009-0007-8466-9201
Llobet, Noemí
Carcelero, Esther
Munárriz, Daniel https://orcid.org/0009-0005-4977-8782
Bladé, Joan https://orcid.org/0000-0002-4563-3405
Rosiñol, Laura https://orcid.org/0000-0002-2534-9239
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FIS PI22/00647, ICI19/00025)
Generalitat de Catalunya (2021SGR01292)
Fundación Científica Asociación Española Contra el Cáncer (LABAE21971FERN)
Fundación Cris contra el Cancer grant reference number TRANSPHYSTALENT_23_6
- License Information
-
More Information
Article History
Received: 4 March 2025
Revised: 7 May 2025
Accepted: 14 May 2025
First Online: 26 May 2025
Competing interests
: LGRL: Honoraria and travel grants from Janssen, Amgen, GSK, BMS, Sanofi, and Menarini Stemline; AD: Honoraria from Janssen, travel grants from Sanofi, Janssen, Binding Side; DFM: Honoraria and travel grants from Janssen; MTC: Honoraria from Janssen, Sanofi, GSA, Amgen, and Pfizer, LR: Honoraria from BMS, Celgene, Amgen, Takeda, Sanofi, Janssen, GSK; JB: Honoraria from Janssen, Celgene, BMS, Amgen, Takeda, Oncopeptides; CFL: Consultancy: BeiGene, Sanofi, GSK, BMS, Janssen; Honoraria: BeiGene, Pfizer, Sanofi, GSK, Takeda, BMS, Janssen; Research Funding: Takeda, Amgen, BMS, Janssen. The rest of the authors declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. The study was approved by the Ethics Committee of the Hospital Clínic de Barcelona. Informed consent was obtained from all participants, authorizing the use of their anonymized clinical data for research purposes.
